Cardiovascular Systems to Release Late-Breaking Coronary Data at C3 Conference

Cardiovascular Systems to Release Late-Breaking Coronary Data at C3 Conference

CSI Also Provided Educational Grant for Conference Lunch Symposium

ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI) (NAS: CSII) , will present data from its ORBIT II study of coronary artery disease in a late-breaking presentation at the 2013 Complex Cardiovascular Catheter Therapeutics (C3) conference in Orlando, Fla.

Dr. Jeffrey Chambers, Metropolitan Heart and Vascular Institute, Minneapolis, will present "Treatment and Procedural Outcomes of the ORBIT II Trial Treating De Novo Severely Calcified Coronary Lesions" on Thursday, June 20,from 2:10 to 2:25 p.m.

ORBIT II is evaluating the safety and effectiveness of the company's orbital atherectomy technology in treating patients with severely calcified coronary lesions. This is the first Investigational Device Exemption study in history to evaluate this difficult-to-treat subset of patients. CSI completed ORBIT II enrollment of 443 patients at 49 U.S. medical centers in November 2012 and submitted its Premarket Approval application to the FDA on March 15, 2013.

CSI also provided an educational grant for the upcoming C3 Orbital Atherectomy System Lunch Symposium.

Lunch Symposium: June 19

WHAT: Leading peripheral arterial disease physicians will share their expertise during a lunch symposium at C3. The symposium will cover peripheral calcified lesions and the usage of orbital atherectomy for plaque modification, as well as advanced techniques to maximize outcomes, and more.


Wednesday, June 19, 12 - 2 p.m.


Gatlin A3, A4

Rosen Shingle Creek

9939 Universal Boulevard

Orlando, Fla.


12 - 12:15 p.m.: Impact of Calcified Lesions and Changing Vessel Compliance with Orbital Atherectomy, Jihad Mustapha, MD, FSCAI

12:15 - 12:30 p.m.: Clinical Evidence Supporting Use of Orbital Atherectomy for Plaque Modification: From Randomized Trials to Registry Data, Raymond Dattilo, MD

12:30 - 12:45 p.m.: Orbital Atherectomy: Advanced Techniques to Maximize Outcomes, Utpal Desai, MD

12:45 - 1:30 p.m.: Prerecorded Case Transmission

1:30 - 1:45 p.m.: Case Presentation

1:45 - 2 p.m.: Case Presentation

CSI Booth at C3: June 17 - 21

Visit CSI at booth #200 from 8 a.m. to 5 p.m. Monday, June 17, through Friday, June 21, to meet the company's calcium experts and learn more about its unique orbital technology.

About Peripheral Arterial Disease

As many as 8 million to 12 million Americans, most over age 65, suffer from PAD, which is caused by the accumulation of plaque in peripheral arteries (commonly the pelvis or leg) reducing blood flow. Symptoms include leg pain when walking or at rest. Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation. With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing faster than the rest of the population.

Millions of patients with PAD may benefit from treatment with orbital atherectomy utilizing the Stealth 360° and Diamondback 360°, minimally invasive catheter systems developed and manufactured by CSI. These systems use a diamond-coated crown, attached to an orbiting shaft, which sands away plaque while preserving healthy vessel tissue — a critical factor in preventing reoccurrences. Balloon angioplasty and stents have significant shortcomings in treating hard, calcified lesions. Stents are prone to fractures and high recurrence rates, and treatment of hard, calcified lesions often leads to vessel damage and suboptimal results.

About Coronary Artery Disease

Coronary Artery Disease (CAD) is a life-threatening condition and leading cause of death in men and women in the United States. CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow. The risk of CAD increases if a person has one or several of the following: high blood pressure, abnormal cholesterol levels, diabetes, or family history of early heart disease. CAD affects an estimated 16.8 million people in the United States and is the most common form of heart disease. Heart disease claims more than 600,000 lives, or 1 in 4 Americans, in the United States each year.

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, nearly 110,000 of CSI's devices have been sold to leading institutions across the United States. CSI has also completed its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States.

For more information, visit the company's website at

Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
Sarah Wozniak, 651-259-1636
Padilla Speer Beardsley Inc.
Matt Sullivan, 612-455-1709
Dave Folkens, 612-455-1741

KEYWORDS: United States North America Florida Minnesota


The article Cardiovascular Systems to Release Late-Breaking Coronary Data at C3 Conference originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.